Kadcyla Not Better Than Standard of Care as First Treatment for Advanced-Stage, HER2-Positive Disease, but Causes Fewer Side Effects | International News Live Blog

https://internationalnewsliveblog.wordpress.com/2017/01/23/kadcyla-not-better-than-standard-of-care-as-first-treatment-for-advanced-stage-her2-positive-disease-but-causes-fewer-side-effects/

Results from the MARIANNE study show that Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine), a targeted therapy medicine, wasn



t better than the targeted therapy Herceptin (chemical name: trastuzumab) plus a taxane chemotherapy medicine as the first treatment for locally advanced or metastatic, HER2-positive breast cancer. Still, … http://internationalnewslive.com/kadcyla-not-better-than-standard-of-care-as-first-treatment-for-advanced-stage-her2-positive-disease-but-causes-fewer-side-effects/